Antiretroviral drug resistance testing in adults infected with human immunodefidency virus type 1: 2003 Recommendations of an International Aids Society-USA panel

Clinical Infectious Diseases

Volumn 37, Issue 1, 2003, Pages 113-128

  Hirsch, Martin S ^a,n   Brun Vézinet, Françoise ^j   Clotet, Bonaventura ^k   Conway, Brian ^l   Kuritzkes, Daniel R ^b   D'Aquila, Richard T ^c   Demeter, Lisa M ^d   Hammer, Scott M ^e   Johnson, Victoria A ^f   Loveday, Clive ^m   Mellors, John W ^g   Jacobsen, Donna M ^h   Richman, Douglas D ⁱ  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

^e Columbia Univ Coll of Phys/Surgs ^*  (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g UNIVERSITY OF PITTSBURGH   (United States)

^h International AIDS Society USA   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j BICHAT HOSPITAL   (France)

^k HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^l UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^m Intl Clinical Virology Centre   (United Kingdom)

ⁿ MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CELL COUNT; CLINICAL TRIAL; CROSS RESISTANCE; DRUG CHOICE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RESISTANCE; LABORATORY TEST; ORGANIZATION; PATIENT CARE; PHENOTYPE; PREGNANCY; PRIORITY JOURNAL; RNA ANALYSIS; SEQUENCE ANALYSIS; TREATMENT FAILURE; UNITED STATES; VIRAL GENETICS; VIROLOGY; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEALTH PLANNING GUIDELINES; HIV INFECTIONS; HIV-1; HLA ANTIGENS; HUMANS; MICROBIAL SENSITIVITY TESTS; PREGNANCY; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

EID: 0038234808     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/375597     Document Type: Article

References (172)

1. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA Panel. JAMA 1998; 279:1984-91.
2. Hirsch MS, Brun-Vézinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000; 283:2417-26.
3. Haubrich RH, Kemper CA, Hellmann NS, et al. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS 2002; 16:F33-40.
4. Mellors J, Vaida F, Bennet K, Hellmann NS, DeGruttola V, Hammer S. Efavirenz hypersusceptibility improves virologic response to multidrug salvage regimens in ACTG 398 [abstract 45]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:69.
5. Gomes P, Diogo I, Goncalves MF, et al. Different pathways to nelfinavir genotypic resistance in HIV-1 subtypes B and G [abstract 46]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:69.
6. Brenner B, Turner D, Oliveira M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to nonnucleoside reverse transcriptase inhibitors. AIDS 2003; 17:F1-5.
7. Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002;296:1439-43.
8. Whitcomb JM, Paxinos E, Huang W, et al. The presence of nucleoside analogue mutations (NAMs) is highly correlated with reduced susceptibility to all nRTIs [abstract 569-T]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:264.
9. Back D, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 2002; 16:S5-37.
10. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243:1731-4.
11. Shulman N, Hughes MD, Winters M, et al. Subtle decreases in stavudine phenotypic susceptibility, predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients. J Acquir Immune Defic Syndr 2002; 31:121-7.
12. Calvez V, Costagliola D, Descamps D, et al. Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trail. Antivir Ther 2002; 7:211-8.
13. Miller V, Larder BA. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antivir Ther 2001;6(Suppl 3):25-44.
14. Ren J, Esnouf RM, Hopkins AL, et al. 3′-Azido-3′-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes. Proc Natl Acad Sci USA 1998; 95:9518-23.
15. Arion D, Kaushik N, McCormick S, Borkow G, Parniak MA. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 1998; 37:15908-17.
16. Arion D, Sluis-Cremer N, Parniak MA. Mechanism by which phosphonoformic acid resistance mutations restore 3′-azido-3′-deoxythymidine (AZT) sensitivity to AZT-resistant HIV-1 reverse transcriptase. J Biol Chem 2000; 275:9251-5.
17. International AIDS Society-USA Resistance Mutations Project Panel. Drug resistance mutations in HIV-1. Top HIV Med 2002; 10:21-5.
18. International AIDS Society-USA Resistance Mutations Project Panel. Drug resistance mutations in HIV-1. Available at: http://www.iasusa.org/resistance_mutations/resistance.pdf. Accessed 3 March 2003.
19. Shirasaka T, Kavlick MF, Ueno T. Emergence of human immunodeficiency virus type-1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995;92:2398-402.
20. Iversen AK, Shafer RW, Wehrly K, et al. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 1996; 70:1086-90.
21. Schmit JC, Van Laethem K, Ruiz L, et al. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. AIDS 1998; 12:2007-15.
22. Kavlick MF, Wyvill K, Yarchoan R, Mitsuya H. Emergence of multidideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy. J infect Dis 1998; 177:1506-13.
23. Larder BA, Bloor S, Kemp SD, et al. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob Agents Chemother 1999; 43:1961-7.
24. de Jong JJ, Goudsmit J, Lukashov VV, et al. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS 1999; 13:75-80.
25. Winters MA, Coolley KL, Girard YA, et al. 6-Basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest 1998; 102:1769-75.
26. Winters MA, Merigan TC. Variants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nucleoside analogs. Antimicrob Agents Chemother 2001; 45:2276-9.
27. Boucher CAB, O'Sullivan E, Mulder JW, et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992; 165:105-10.
28. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989; 246:1155-8.
29. Kellam P, Boucher CA, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 1992; 89:1934-8.
30. Lennerstrand J, Hertogs K, Stammers DK, Larder BA. Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants. J Virol 2001; 75:7202-5.
31. Mas A, Parera M, Briones C, et al. Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance. EMBO J 2000; 19:5752-61.
32. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269:696-9.
33. St Clair MH, Martin JL, Tudor-Williams G, et al. Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991; 253:1557-9.
34. Gotte M, Arion D, Parniak MA, Wainberg MA. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol 2000; 74:3579-85.
35. Nijhuis M, Schuurman R, de Jong D, et al. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. J Infect Dis 1997; 176:398-405.
36. Kemp SD, Shi C, Bloor S, Harrigan PR, Mellors JW, Larder BA. Novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to AZT and 3TC. J Virol 1998; 72:5093-8.
37. Kuritzkes D, Shugarts D, Bakhtiari M, et al. Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy. J Acquit Immune Defic Syndr 2000; 23:26-34.
38. Naeger LK, Margot NA, Miller MD. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication. Antivir Ther 2001; 6:115-26.
39. Ross L, Scarsella A, Raffanti S, et al. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens. AIDS Res Hum Retroviruses 2001; 17:1107-15.
40. Miller MD, McKenna P, Larder BA, Harrigan PR. Characteristics of tenofovir phenotypic susceptibility [abstract 8]. Antivir Ther 2001; 6(Suppl 1):7.
41. Scott WA. The enzymatic basis for thymidine analogue resistance in HIV-1. AIDS Rev 2001;3:194-200. Available at: http://www.aidsreviews.com/fr_2001.html.
42. Miller MD, Zhong L, Chen S, Margot NA, Wulfsohn M. Multivariate analyses of antiviral response to tenofovir DF therapy in antiretroviral-experienced patients. Antivir Ther 2002; 7(Suppl 1):S16.
43. Hsiou Y, Ding J, Das K, et al. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J Mol Biol 2001; 309:437-45.
44. Delaugerre C, Rohban R, Simon A, et al. Resistance profile and crossresistance to HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol 2001; 65:445-8.
45. Whitcomb JM, Huang W, Limoli K, et al. Hypersusceptibility to nonnucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. AIDS 2002; 16:F41-7.
46. Shulman N, Zolopa AR, Passaro D, et al. Phenotypic hypersusceptibility to non-nudeoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. AIDS 2001; 15:1125-32.
47. Swanstrom R, Katzenstein D, Hellmann NS, et al. Selection for delavirdine (DLV) resistance is not associated with loss of nucleoside analogue (NRTI) resistance mutations in subjects with non-nucleoside analogue (NNRTI) hypersusceptibility - results from ACTG 359 [abstract 567-T]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:263.
48. Kemper CA, Witt MD, Keiser PH, et al. Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors. AIDS 2001; 15:609-15.
49. Maguire M, Shortino D, Klein A, et al. Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob Agents Chemother 2002; 46:731-8.
50. Lorenzi P, Opravil M, Hirschel B, et al. Impact of drug resistance mutations on virologic response to salvage therapy. AIDS 1999; 13:F17-21.
51. Condra JH, Schleif WA, Blahy OM. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374:569-71.
52. Ziermann R, Limoli K, Das K, Arnold E, Petropoulos CJ, Parkin NT. A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. J Virol 2000; 74:4414-9.
53. Zachary KC, Hanna GJ, D'Aquila RT. Human immunodefidencyvirus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo. Clin infect Dis 2001; 33:2075-7.
54. Obry V, Race E, Vray M, et al. Hypersusceptibility to protease inhibitors associated with mutated proteases at codons 30 and 88 in treated patients [abstract 557-T]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:260.
55. Martinez-Picado J, Savara AV, Shi L, Sutton L, D'Aquila RT. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. Virology 2000; 275:318-22.
56. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998; 4:1302-7.
57. Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 1998; 72:986-93.
58. Greeberg ML, Melby T, Sista P, et al. Baseline and on-treatment susceptibility to enfuvirtide seen in TORO 1 and TORO 2 to 24 weeks [abstract 141]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003:108.
59. Back NK, Nijhuis M, Keulen W, et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996; 15:4040-9.
60. Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, Lamarre D. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol 1997; 71:1089-96.
61. Gerondelis P, Archer RH, Palaniappan C, et al. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5′-end- and DNA 3′-end-directed RNase H activities. J Virol 1999; 73:5803-13.
62. Archer RH, Dykes C, Gerondelis P, et al. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture. J Virol 2000; 74:8390-401.
63. Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 1999;73:3744-52.
64. Bleiber G, Munoz M, Ciuffi A, Meylan P, Telenti A. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1. J Virol 2001; 75:3291-300.
65. Dykes C, Fox K, Lloyd A, Chiulli M, Morse E, Demeter LM. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants. Virology 2001; 285:193-203.
66. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472-80.
67. Quinones-Mateu ME, Ball SC, Marozsan AJ, et al. A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J Virol 2000; 74:9222-33.
68. Collin G, Descamps D, Telles F, et al. Differences in protease and reverse transcriptase sequences between the TruGene HIV-1 genotyping kit (Visible Genetics) and the ViroSeq genotyping system (PE Applied Biosystems) [abstract 68]. Antivir Ther 2000; 5(Suppl 3):53.
69. Hoover ML, Wentworth DN, Neaton JD, et al. A blinded comparison of two sequencing assays for resistance mutations in HIV-1 protease and reverse transcriptase genes in the GART Study (CPCRA 046) [abstract 78]. Antivir Ther 2000; 5(Suppl 4):60.
70. Brun-Vezinet F, Descamps D, Calvez V, et al. Quality control assessment for HIV-1 drug resistance sequencing [abstract 157]. Antivir Ther 2001;6(Suppl 1):121.
71. Keulen W, Brambilla D, Buimer M, et al. A study on HIV-1 genotyping proficiency in 125 laboratories, using the ENVA-3 panel [abstract 166]. Antivir Ther 2001;6(Suppl 1):127.
72. Schuurman R, Demeter L, Reichelderfer P, Tijnagel J, de Groot T, Boucher C. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol 1999; 37:2291-6.
73. Wensing AM, Keulen W, Buimer M, Brambilla D, Schuurman R, Boucher C. Analysis of the world-wide evaluation study on HIV-1 genotype interpretation; ENVA-3 [abstract 133]. Antivir Ther 2001; 6(Suppl 1):101.
74. Sharer RW, Gonzales MJ, Brun-Vezinet F. Online comparison of HIV-1 drug resistance algorithms identifies rates and causes of discordant interpretations [abstract 134]. Antivir Ther 2001; 6(Suppl 1):101.
75. Cingolani A, Antinori A, Rizzo MG, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002; 16:369-79.
76. Lanier ER, Hellman N, Scott J, et al. Determination of a clinically relevant phenotypic resistance "cutoff" for abacavir using the PhenoSense assay [abstract 254]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 2001:117.
77. Kempf D, Brun S, Rode R, et al. Identification of clinically relevant phenotypic and genotypic break-points for ABT-378/r in multiple PI-experienced, NNRTI-naive patients [abstract 89]. Antivir Ther 2000; 5(Suppl 3):70.
78. Calvez V, Costagliola D, Descamps D, et al. Resistance and viral response to stavudine/lamivudine combination in zidovudine, didanosine and zalcitabine experienced patients in the ALTIS 2 ANRS trial [abstract 107]. Antivir Ther 2000; 5(Suppl 3):83.
79. Shulman N, Shafer R, Winters M, et al. Genotypic predictors of virologic response to stavudine after zidovudine monotherapy (ACTG 302) [abstract 437]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 2001:173.
80. Calvez V, Cohen-Codar I, Marcelin AG, et al. Identification of individual mutations in HIV protease associated with virological response to lopinavir/ritonavir therapy [abstract 82]. Antivir Ther 2001; 6(Suppl 1):64.
81. Costagliola D, Descamps D, Calvez V, et al. Presence of thymidine-associated mutations and response to d4T, abacavir and ddl in the control arm of the Narval ANRS 088 trial [abstract 450]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 2001:177.
82. Miller MD, Margot N, Coakley D, Cheng A. Anti-HIV responses and development of RT mutations in antiretroviral-experienced patients adding tenofovir DF (TDF) therapy: baseline and week 24 genotypic analyses of study 907 [abstract 1928]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001:345.
83. Larder BA, Kemp SD, Hertogs K. Quantitative prediction of HIV-1 phenotypic drug resistance from genotypes: the virtual phenotype (VirtualPhenotype) [abstract 63]. Antivir Ther 2000; 5(Suppl 3):49.
84. Paxinos EE, Sartoris MM, Dawson K, et al. Natural variation in susceptibility to nonnucleoside reverse transcriptase inhibitors predates drug availability [abstract 156]. Antivir Ther 2000; 5(Suppl 3):123.
85. Qari SH, Respess R, Weinstock H, et al. A comparative analysis of Virco Antivirogram and ViroLogic PhenoSense phenotypic assays for drug susceptibility of HIV-1 [abstract 62]. Antivir Ther 2000; 5(Suppl 3):49.
86. Dam E, Clavel F, Calvez V, et al. Comparison of HIV-1 resistance phenotypes obtained by two different assay systems [abstract 158]. Antivir Ther 2001;6(Suppl 1):122.
87. Miller V, Schuurman R, Clavel F, et al. Comparison of HIV-1 drug susceptibility (phenotype) results reported by three major laboratories [abstract 169]. Antivir Ther 2001;6(Suppl 1):129.
88. Wrin T, Huang W, Yap J, et al. Evaluating HIV-1 co-receptor usage and inhibitors of virus entry using recombinant virus assays [abstract 1]. Antivir Ther 2001;6(Suppl 1):3.
89. Obry V, Costagliola D, Race E, et al. The extent of association between resistance phenotype and treatment response is highly dependent upon the drug [abstract 78]. Antivir Ther 2001;6(Suppl 1):61.
90. Haubrich R, Keiser P, Kemper C, et al. CCTG 575: a randomized, prospective study of phenotype testing versus standard of care for patients failing antiretroviral therapy [abstract 80]. Antivir Ther 2001; 6(Suppl 1):63.
91. Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the VIRADAPT Study. AIDS 2000; 14:1333-9.
92. Kempf D, Hsu A, Jiang P, et al. Response to ritonavir (RTV) intensification in indinavir (IDV) recipients is highly correlated with virtual inhibitory quotient [abstract 523]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 2001:200.
93. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353:2195-9.
94. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 14:F83-93.
95. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16:209-18.
96. Cohen C, Hunt S, Sension M, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002; 16:579-88.
97. Meynard JL, Vray M, Morand-Joubert L, et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 2002; 16:727-36.
98. Mayers D. Both antiretroviral drug levels and drug resistance are associated with short-term virologic responses to subsequent drug regimens in CPCRA 046 (GART Study) [abstract 124]. In: Program and abstracts of the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment (Buenos Aires). Stockholm: International AIDS Society, 2001:122.
99. Salama C, Policar M, Cervera C. Knowledge of genotypic resistance mutations among providers of care to patients with human immunodeficiency virus. Clin Infect Dis 2003; 36:101-4.
100. Melnick D, Rosenthal J, Cameron M, et al. Impact of phenotypic antiretroviral drug resistance testing on the response to salvage antiretroviral therapy (ART) in heavily experienced patients [abstract 786]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2000:222.
101. Meynard JL, Vray M, Morand-Joubert L, et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure. AIDS 2002; 16:727-36
102. Vray M, Meynard JL, Dalban C, et al. Multivariate logistic regression analysis of factors predictive of the virological response in the Narval trial [abstract B1387]. In: Program and abstracts of the 14th International AIDS Conference (Barcelona). Barcelona: Prous Science, S.A., 2002:377.
103. Wegner S, Wallace M, Tasker S, et al. Long-term clinical efficacy of resistance testing: results of the CERT trial [abstract 158]. Antivir Ther 2002; 7:S129.
104. Blanco JL, Valdecillos G, Arroyo JR, et al. A prospective randomized study on the usefulness of genotypic resistance tests versus real phenotypic resistance tests in heavily pretreated patients with virological failure (VIHRES Study) [abstract TuPeB4624]. In: Program and abstracts of the 14th International AIDS Conference (Barcelona). Barcelona: Prous Science, S.A., 2002:421.
105. Perez-Elias MJ, Garcia I, Munoz V, et al. A randomized, prospective study of phenotype (P) versus virtual phenotype (virtualP) testing for patients failing antiretroviral therapy (ARVT): final analysis [abstract H-1079]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002:268.
106. Parkin N, Chappey C, Maroldo L, et al. Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information. J Acquir Immune Defic Syndr 2002; 31:128-36.
107. Lalezari J, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-85.
108. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-95.
109. Weinstein MC, Goldie SJ, Losina E, et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med 2001; 134:440-50.
110. Verhofstede C, Van Wanzeele F, Van Der Gucht B, De Cabooter N, Plum J. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS 1999; 13:2541-6.
111. Miller V, Sabin C, Hertogs K, et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000; 14:2857-67.
112. Devereux HL, Youle M, Johnson MA, Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999; 13:F123-7.
113. Joly V, Descamps D, Zeng F, et al. Evolution of HIV-1 resistance mutations to nonnucleoside reverse transcriptase inhibitors (NNRTIs) following withdrawal [abstract 123]. In: Program and abstracts of the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment (Buenos Aires). Stockholm: International AIDS Society, 2001:122.
114. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994; 68:1660-6.
115. Little SJ, Daar ES, Holte S, et al. Persistence of transmitted drug resistance among subjects with primary HIV infection not receiving antiretroviral therapy [abstract 95]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:83.
116. Little SJ, Holte S, Routy JR et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-94.
117. Salomon H, Wainberg MA, Brenner B, et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS 2000; 14:F17-23.
118. Duwe S, Brunn M, Altmann D, et al. Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. J Acquir Immune Defic Syndr 2001; 26:266-73.
119. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 2001;322:1087-8.
120. Zaidi I, Weinstock H, Woods T, Thomas J, Heneine W, Kaplan J. Prevalence of mutations associated with antiretroviral drug resistance among HIV-1-infected persons in 10 US cities, 1997-2000 [abstract 155]. Antivir Ther 2001;6(Suppl 1):118.
121. Briones C, Perez-Olmeda M, Rodriguez C, del Romero J, Hertogs K, Soriano V. Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid. J Acquit Immune Defic Syndr 2001; 26:145-50.
122. Yerly S, Vora S, Rizzardi P, et al. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 2001; 15:2287-92.
123. + T cell responses associated with control of viremia. Science 1997; 278:1447-50.
124. Musey LK, Krieger JN, Hughes JP, Schacker TW, Corey L, McElrath MJ. Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection. J Infect Dis 1999; 180:278-84.
125. Gallego O, Ruiz L, Vallejo A, et al. Changes in the rate of genotypic resistance to antiretroviral drugs in Spain. AIDS 2001; 15:1894-6.
126. Hanna GJ, Balaguera HU, Freedberg KA, et al. Drug-selected resistance mutations and non-B subtypes in antiretroviral-naive adults with established human immunodeficiency virus infection. J Infect Dis (in press).
127. Wegner S, Brodine S, Mascola J, et al. High frequency of antiretroviral drug resistance in HIV-1 from recently infected therapy-naive individuals [abstract 119]. Antivir Ther 1999;4(Suppl 1):85.
128. Verbiest W, Schel P, Conant M, et al. An epidemiological perspective survey assessing the prevalence of HIV-1 drug resistance in 230 HIV-1-positive antiretroviral-naive patients from the USA [abstract 122]. Antivir Ther 1999;4(Suppl 1):86-7.
129. Descamps D, Costagliola D, Glaude G, et al. Prevalence of resistance mutations in antiretroviral-naive patients: French National Study [abstract 123]. Antivir Ther 1999;4(Suppl 1):87.
130. Harrigan PR, Alexander C, Dong W, Jahnke N, O'Shaughnessy M, Montaner JS. Prevalence of resistance-associated mutations in patients starting antivirals: virological response after approximately 1 year of therapy [abstract 124]. Antivir Ther 1999;4(Suppl 1):88.
131. Brenner BG, Routy JP, Petrella M, et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002; 76:1753-61.
132. De Ronde A, van Dooren M, van der Hoek L, et al. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J Virol 2001; 75:595-602.
133. Richman DD, Bozzette S, Morton S, et al. The prevalence of antiretroviral drug resistance in the US [abstract LB-17]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology. 2001:S129.
134. D'Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995; 122:401-8.
135. Call SA, Saag MS, Westfall AO, et al. Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection. J Infect Dis 2001; 183:401-8.
136. Japour AJ, Welles S, D'Aquila RT, et al. Prevalence and clinical significance of zidovudine (ZDV) resistance mutations in human immunodeficiency virus isolated from patients following long-term zidovudine treatment. J Infect Dis 1995; 171:1172-9.
137. Miller V, Phillips A, Rottmann C, Staszewski S. Dual resistance to zidovudine (ZDV) and lamivudine (3TC) in patients treated with ZDV/3TC combination therapy: association with therapy failure. J Infect Dis 1998; 177:1521-32.
138. Harrigan PR, Montaner JS, Hogg RS, et al. Baseline resistance profile predicts response to ritonavir/saquinavir therapy in a community setting [abstract 55]. Antivir Ther 1998;3(Suppl 1):38.
139. Zolopa AR, Sharer RW, Warford A, et al. HIV-1 genotype resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med 1999; 131:813-21.
140. Deeks SG, Hellman NS, Grant RM, et al. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis 1999; 179:1375-81.
141. Clevenbergh P, Durant J, Halfon P, et al. Persisting long-term benefit of antiretroviral genotypic guided treatment for HIV-infected patients failing HAART: the VIRADAPT study, week 48 follow-up [abstract 60]. Antivir Ther 1999;4(Suppl 1):42.
142. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Merigan TC, CPRCA 046 Study Team. Final results of CPRCA 046: a pilot study of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy [abstract 61]. Antivir Ther 1999; 4(Suppl 1):43.
143. Havlir DV, Hellmann NS, Petropoulos CJ, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavircontaining regimens. JAMA 2000; 283:229-34.
144. Descamps D, Flandre P, Calvez V, et al. Mechanisms of virologic failure in previously untreated HIV-1 infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team [see comments]. JAMA 2000; 283:205-11.
145. De Pasquale MP, Murphy R, Kuritzkes D, et al. Resistance during early virological rebound on amprenavir plus zidovudine plus lamivudine triple therapy or amprenavir monotherapy in ACTG protocol 347 [abstract 71]. Antivir Ther 1998; 3(Suppl 1):50-1.
146. Bacheler L, Ploughman L, Hertogs K, Larder B. Impact of baseline NNRTI resistance on the efficacy of efavirenz combination therapy in NNRTI therapy-naive patients (study DMP 266-006) [abstract 88]. Antivir Ther 2000; 5(Suppl 3):70.
147. Yeni PG, Hammer SM, Carpenter CCJ, et al. Antiretroviral treatment for adult HIV-1 infection in 2002: updated recommendations of the International AIDS Society-USA panel. JAMA 2002; 288:222-35.
148. Fiscus SA, Adimora AA, Schoenbach VJ, et al. Trends in human immunodeficiency virus (HIV) counseling, testing, and antiretroviral treatment of HIV-infected women and perinatal transmission in North Carolina. J Infect Dis 1999; 180:99-105.
149. US Public Health Service. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Updated 4 February 2002. Available at: http://www.aidsinfo.nih.gov/guidelines/perinatal/Perinatal.pdf. Accessed 28 February 2003.
150. US Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. 4 February 2003. Available at: http://www.aidsinfo.nih.gov/guidelines/adult/AAMay23.pdf. Accessed 28 February 2002.
151. Masquelier B, Chaix ML, Burgard M, et al. Zidovudine genotypic resistance in HIV-1-infected newborns in the French perinatal cohort. J Acquir Immune Defic Syndr 2001;27:99-104.
152. Jackson JB, Becker-Pergola G, Guay LA, et al. Identification of the K103N resistance mutation in Ugandan womeu receiving nevirapine to prevent HIV- 1 vertical transmission. AIDS 2000; 14:F111-5.
153. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical trausmission (HIVNET 012). AIDS 2001; 15:1951-7.
154. Lawrence J, Mayers D, Huppler-Hullsiek K, et al. CPCRA 064: a randomized trial examining structured treatment interruption for patients failing therapy with multi-drug resistant HIV [abstract 67]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003:81.
155. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1996; 335:1621-9.
156. Johnson VA, Petropoulos CJ, Woods CR, et al. Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. J Infect Dis 2001; 183:1688-93.
157. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-300.
158. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replicationcompetent HIV despite prolonged suppression of plasma viremia. Science 1997; 278:1291-5.
159. Katlama C, Dominguez S, Duvivier C, et al. GIGHAART (ANRS 097): a prospective randomized trial comparing the efficacy of a salvage regimen administered with or without treatment interruption in patients with severe biological failure and extensive prior therapy [abstract 16]. In: Program and abstracts of the 8th European Conference on Clinical Aspects and Treatment of HIV-Infection (Athens). Athens: European AIDS Clinical Society, 2001:81.
160. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472-80.
161. Ruiz L, Ribera E, Bonjoch A, et al. Virologic and immunologic benefit of a salvage therapy that includes Kaletra plus Fortovase preceded or not by antiretroviral therapy interruption (TI) in advanced HIV-infected patients (6-month-follow-up) [abstract 421]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:212.
162. Daar ES, Bai J, Hausner MA, Majchrowicz M, Tamaddon M, Glörgi JV. Acute HIV syndrome after discontinuation of antiretroviral therapy in a patient treated before seroconversion. Ann Intern Med 1998; 128:827-9.
163. Kilby JM, Goepfert PA, Miller AP, et al. Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: a case report. Ann Intern Med 2000; 133:435-8.
164. Tremblay CL, Hicks JL, Sutton L, et al. Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV-1 infection. AIDS 2003; 17:1086-9.
165. Martinez-Picado J, Morales-Lopetegi K, Wrin T, et al. Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. AIDS 2002; 16:895-9.
166. Lundgren JD, Vella S, Paddam L, et al. Interruption/stopping antiretroviral therapy and the risk of clinical disease: results from the EuroSIDA study [abstract 48]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002:70.
167. Fiette P, Monnet A, Lloyd R, Naudin C. Use of novel set of RT-CPR primers in conjunction with Trugene HIV-1 genotyping kit provides reliable genotypes of difficult patient specimens [abstract 263]. In: Program and abstracts of the 8th European Conference on Clinical Aspects and Treatment of HIV Infection (Athens). Athens: European AIDS Clinical Society, 2001:169.
168. Grossman Z, Vardinon N, Chemtob D, et al. Mutations in naive and treated clade C patients [abstract 162]. Antivir Ther 2000; 5(Suppl 3): 127.
169. Boulmé R, Dugas O, Halfon P, Diaz R, Schmit JC. Analysis of mutational patterns associated with resistance to tenofovir DF and lopinavir/ritonavir [abstract P352]. In: Program and abstracts of the 8th European Conference on Clinical Aspects and Treatment of HIV Infection (Athens). Athens: European AIDS Clinical Society, 2001:213.
170. Barlotta C, Facchi G, Violin M. High prevalence of HIV-1 circulating recombinant forms among non-clade B strains in Italy [abstract P354]. In: Program and abstracts of the 8th European Conference on Clinical Aspects and Treatment of HIV Infection (Athens). Athens: European AIDS Clinical Society, 2001:214.
171. Caride E, Hertogs K, Larder B, et al. Genotyping and phenotyping analysis orb and non-B HIV-1 subtypes from Brazilian patients under HAART [abstract 164]. Antivir Ther 2000;5(Suppl 3):129.
172. Lambert C, Fontaine E, Servais J, et al. Drug resistance-related mutations in the pol gene of non-subtype B HIV-1 patient strains [abstract 165]. Antivir Ther 2000;5(Suppl 3):129.